Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Korro Bio (KRRO) Climbs +32% on Clinical Milestones and Q3 Results

Korro Bio (KRRO) Climbs +32% on Clinical Milestones and Q3 Results

Key Takeaways

  • Korro Bio (KRRO) shares rose roughly 32% over the trailing 30 days, climbing from about $9.29 to approximately $12.25.
  • The move was driven by a first-in-human clinical milestone for KRRO-121, an FDA rare pediatric disease designation, and stronger-than-expected third-quarter results.
  • Favorable analyst coverage, with the majority of firms maintaining Buy ratings and price targets ranging from $15 to $30, supported the rally.
  • Over the past quarter the stock has been highly volatile, trading between roughly $8.34 and $17, and remains modestly below its mid-August level.
  • Novo Nordisk's decision to terminate its research collaboration introduced a headwind, while the company's cash runway extends into the second half of 2028.
  • Explore additional pages for Price Targets, Earnings, and Forecast data on Korro Bio.
  • Discover Trending AI Robots to see how automated strategies are tracking stocks like KRRO.

Company Overview: Korro Bio's (KRRO) RNA-Editing Platform

Korro Bio is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, advancing genetic medicines via its OPERA RNA-editing platform. The approach uses the body's natural RNA-editing processes for precise, temporary single-base corrections, which expands options in genetic medicine and lowers the chance of lasting off-target effects compared with DNA-editing methods.

The lead candidate, KRRO-121, targets urea cycle disorders and hepatic encephalopathy, while KRRO-111 focuses on alpha-1 antitrypsin deficiency. I follow KRRO closely for its differentiated technology, progress in both rare and more common liver conditions, and the upcoming clinical and regulatory events that could shift its valuation.

KRRO Stock Performance: Recent 30-Day Gain vs. Quarterly View

Over the past 30 days, KRRO advanced approximately 32%, moving from a closing price near $9.29 to roughly $12.25. The path was uneven, with a strong surge late in October followed by some pullback in mid-November as early excitement around the earnings release eased.

The three-month picture shows more restraint. About three months ago the stock traded near $12.96, so KRRO is down approximately 5% for the full quarter even after the recent move. Volatility has been pronounced, with a low near $8.34 in mid-October and an intraday peak above $17 in early November. This pattern is typical for a clinical-stage biotech where pipeline news drives swings more than near-term sales.

Key Drivers Behind the 30-Day Advance in KRRO

Several concrete developments supported the gain. On November 5, Korro Bio released third-quarter 2026 results showing a net loss of approximately $17.5 million and an adjusted per-share loss of about $0.98, better than consensus estimates near $1.26. The company also began dosing healthy volunteers in the Phase 1/2 ANCHOR trial of KRRO-121 and received FDA rare pediatric disease designation for the program.

KRRO-111 delivered more than 95% SERPINA1 mRNA editing in preclinical work, underscoring platform strength. Cash, cash equivalents, and marketable securities stood at $124.8 million at quarter-end, supporting operations into the second half of 2028. Analyst notes added lift, with Oppenheimer at a $22 target, Citi at $21, and Piper Sandler at $30, all Buy-rated; RBC Capital held a $10 target and Neutral stance. A counterpoint arrived when Novo Nordisk notified Korro on November 3 that it would end the research collaboration and license agreement, effective February 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Quarterly Context and Pipeline Transition for KRRO

Over the trailing three months, KRRO moved within a wide range as investors balanced pipeline progress against ongoing losses and cash use. A decline in September and early October pushed shares toward multi-month lows before positive clinical updates and supportive analyst commentary fueled a recovery into early November.

The broader story centers on moving Korro's lead assets from preclinical into clinical stages. First-in-human dosing for KRRO-121 and robust preclinical editing data for KRRO-111 represented an inflection that the market rewarded, even as the Novo Nordisk collaboration wind-down and lack of near-term revenue prevented the stock from holding its early-November peaks.

What to Watch Next for KRRO Stock

Clinical execution remains the primary catalyst. Continued enrollment and dosing in the Phase 1/2 ANCHOR trial of KRRO-121, with patient dosing in urea cycle disorders expected in the first half of 2027 and an interim readout in the second half of 2027, will be closely followed. Korro has also guided toward a regulatory submission for KRRO-111 in the first half of 2027.

Financial management and the cash runway stay important given persistent losses. Updates on the Novo Nordisk collaboration wind-down and remaining deferred revenue could affect quarterly results. Sector sentiment around genetic medicines, shifts in analyst targets, and competitive moves in RNA editing will also matter. As with any clinical-stage biotech, outcomes hinge on trial data.

How Tickeron AI Tools Support My Biotech Research

When tracking names like KRRO, I often review automated strategies on Tickeron’s Trending AI Robots page. It surfaces top-performing bots from a broad universe, letting me compare approaches across timeframes and risk levels without sifting through every option. This adds a practical layer to traditional analysis and helps gauge how algorithmic systems are positioned around clinical-stage stocks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KRRO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


KRRO's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 27 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 109 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.596). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -9%. For the same Industry, the average monthly price growth was -16%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
60 First Street
Phone
+1 617 468-1999
Employees
104
Web
https://www.korrobio.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.